Q-omics provides the consensus-scored GNG5 profile across patient tissues and cancer cell-line models. GNG5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GNG5 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, GNG5 RNA expression shows 18,900 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where GNG5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNG5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNG5 survival associations across molecular data types. GNG5 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNG5 RNA expression–survival associations across cancer types. High GNG5 expression shows unfavorable associations in ACC, LIHC, KIRP and LGG, but favorable associations in COAD and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GNG5 RNA expression.
This table summarizes GNG5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GNG5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNG5 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, STAD, LIHC and KIRP. The BLCA box plot shows higher GNG5 RNA expression in tumor versus normal tissue (log2 FC = +0.847, t-test p < 0.001).
This table shows molecular features associated with GNG5 in patient tissues and cancer cell lines. In patient samples, GNG5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNG5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
